PDS Biotechnology Corporation Common Stock
PDSBPDS Biotechnology Corporation (PDSB) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The company leverages its proprietary Versamune® platform to stimulate the body's immune response and has a portfolio of product candidates targeting various cancers and infectious diseases. Based in the United States, PDS Biotechnology aims to create innovative treatments with the potential for durable immune responses.
Company News
The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developme...
PDS Biotechnology announced a registered direct offering of 5.8 million shares and warrants, expecting to raise $5.3 million upfront with potential additional $5.8 million from warrant exercises. The proceeds will support the VERSATILE-003 Phase 3 clinical trial and other research and development expenses.
PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.
PDS Biotechnology Corporation announced that it granted 7,000 nonstatutory stock options to an employee as a material inducement to employment. The options have an exercise price of $2.25 and vest over a four-year period.
PDS Biotech announced positive results from its Phase 2 IMMUNOCERV trial, showing a 36-month overall survival rate of 84.4% in locally advanced cervical cancer patients treated with Versamune® HPV and chemoradiation.
